

DAI-ICHI KARKARIA LTD.  
REGD.OFFICE: LIBERTY BUILDING, SIR VITHALDAS THACKERSEY MARG,  
MUMBAI 400 020.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER  
ENDED 30th SEPTEMBER 2005

PARTICULARS	Quarter ended 30-09-2005 Rs./lacs ( Unaudited )	Quarter ended 30-09-2004 Rs./lacs ( Unaudited )	Half Year Ended 30-09-2005 Rs./lacs ( Unaudited )	Half Year Ended 30-09-2004 Rs./lacs ( Unaudited )	Year ended 31-03-2005 Rs./lacs Audited
1. Net Sales/Other Operating Income	1,538	1,112	2,812	2,204	4,664
2. Other Income	467	33	511	125	166
3. Total Expenditure	1,561	1,105	2,800	2,177	4,531
a) (Increase)/Decrease in stock in trade	(58)	(65)	8	(140)	(49)
b) Consumption of raw and packing materials	1,029	778	1,811	1,484	2,983
c) Staff Cost	187	164	358	331	674
d) Other expenditure	403	228	623	502	923
4. Interest	26	56	64	88	175
5. Depreciation	55	54	108	107	215
6. Profit/(Loss) before tax	363	(70)	351	(43)	(91)
7. Exceptional Item	15	22	29	43	10
8 Profit/(Loss) After Exceptional Item	348	(92)	322	(86)	(101)
9. Provision for taxation					
a) Current Tax	28	0	28	0	2
b) Deferred Tax	0	0	0	0	41
10. Profit/(Loss) after Tax	320	(92)	294	(86)	(144)
11. Add/(Less) : Prior Year's adjustment	0	0	0	0	0
12. Net Profit/(Loss)	320	(92)	294	(86)	(144)
13. Paid-up Equity Share Capital (Face value Rs.10/- per share)	761	761	761	761	761
14. Reserves excluding Revaluation Reserves.	0	0	0	0	3,286
15. Earning Per Share	4.21	(1.21)	3.87	(1.13)	(1.90)
16. Earning Per Share (excluding exceptional items)	4.40	(0.92)	4.25	(0.57)	(1.76)
17. Aggregate Non-Promoter Shareholding. No. of shares	3,078,890	2,954,502	3,078,890	2,954,502	2,954,002
Percentage of Shareholding	40.48%	38.84%	40.48%	38.84%	38.84%

--2--

SEGMENT - WISE REVENUE, RESULT AND CAPITAL EMPLOYED	Quarter ended 30-09-2005 Rs./lacs (Unaudited)	Quarter ended 30-09-2004 Rs./lacs (Unaudited)	Half Year Ended 30-09-2005 Rs./lacs (Unaudited)	Half Year Ended 30-09-2004 Rs./lacs (Unaudited)	Year ended 31-03-2005 Rs./lacs (Audited)
1. SEGMENT REVENUE					
-----					
a) Speciality Chemicals	1,354	942	2,394	1,921	3,950
b) Drugs & Formulations	237	195	515	325	861
c) Unallocated	414	8	414	83	20
	-----	-----	-----	-----	-----
Total	2,005	1,145	3,323	2,329	4,831
Less: Inter Segment Revenue	0	0	0	0	0
	-----	-----	-----	-----	-----
Net Sales/Income from Operations	2,005	1,145	3,323	2,329	4,831
2. Segment Result Profits/(Loss) before tax and interest from					
-----					
a) Speciality Chemicals	3	7	27	47	65
b) Drugs & Formulations	(43)	(28)	(55)	(83)	7
c) Unallocated	414	8	414	83	12
	-----	-----	-----	-----	-----
Total	374	(13)	386	47	84
Less:					
i) Interest	26	56	64	88	175
ii) Other unallocable expenditure net of unallocable income	0	1	0	2	0
	-----	-----	-----	-----	-----
Total (Loss)/Profit before tax	348	(70)	322	(43)	(91)
3. Capital Employed - Net					
-----					
a) Chemicals	3,664	3,355	3,664	3,355	3,009
b) Bulk Drugs & Formulations	2,602	2,761	2,602	2,761	2,857
c) Unallocated common assets	251	468	251	468	614
	-----	-----	-----	-----	-----
	6,517	6,584	6,517	6,584	6,480

Notes:

1. The above financial statement was reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 25th October 2005.
2. Other Income includes interest of Rs 200 lakhs and profit on buyback of investments of Rs 210 lakhs.
3. The exceptional item includes amortisation of retirement benefits to employees under Voluntary Retirement Scheme.
4. Subsequent to September 30, 2005, the company has executed a business transfer agreement to assign its Hyderabad unit, as a going concern and on a slump sale basis to a joint venture company, in which the company shall have twenty percent equity interest. The company has also executed a joint venture cum shareholders agreement. All adjustments relating to this transaction shall be recognised in the quarter ending December 31, 2005.
5. Current tax includes tax on Capital Gains Rs 24 lakhs and Fringe Benefit tax Rs 4 lakhs. Tax on operating results ( including deferred tax ) will be recognised at the end of the year after considering carry forward unabsorbed losses.
6. During the quarter total 6 (SIX) investor complaints were received, which were resolved by the company. No complaints were pending either at the beginning or at the end of the quarter.
7. The Statutory Auditors of the Company have conducted the limited review of the Accounts.
8. The company has identified its main business segments as : (a) Speciality Chemicals and (b) Drugs & Formulations
9. Figures for previous period/ year have been regrouped/ reclassified, wherever necessary.

For & on behalf of the Board of Directors

Place: Mumbai  
Date: October 25, 2005.

S.F.Vakil  
VICE CHAIRPERSON & MANAGING DIRECTOR







This document was created with Win2PDF available at <http://www.win2pdf.com>.  
The unregistered version of Win2PDF is for evaluation or non-commercial use only.  
This page will not be added after purchasing Win2PDF.